1,986 Shares in Repligen Co. (NASDAQ:RGEN) Bought by Peapack Gladstone Financial Corp

Peapack Gladstone Financial Corp acquired a new stake in shares of Repligen Co. (NASDAQ:RGEN) during the third quarter, Holdings Channel.com reports. The firm acquired 1,986 shares of the biotechnology company’s stock, valued at approximately $296,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Tidal Investments LLC raised its position in Repligen by 142.8% in the 3rd quarter. Tidal Investments LLC now owns 11,149 shares of the biotechnology company’s stock worth $1,659,000 after purchasing an additional 6,558 shares during the period. Sanctuary Advisors LLC bought a new position in shares of Repligen during the third quarter valued at approximately $233,000. Coldstream Capital Management Inc. raised its holdings in shares of Repligen by 11.8% in the third quarter. Coldstream Capital Management Inc. now owns 2,194 shares of the biotechnology company’s stock worth $327,000 after buying an additional 231 shares during the period. Resources Management Corp CT ADV purchased a new position in Repligen during the 3rd quarter valued at $37,000. Finally, M&T Bank Corp grew its position in Repligen by 5.9% in the 3rd quarter. M&T Bank Corp now owns 3,166 shares of the biotechnology company’s stock valued at $471,000 after acquiring an additional 177 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on RGEN. Wells Fargo & Company assumed coverage on Repligen in a research report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 target price for the company. Royal Bank of Canada restated an “outperform” rating and issued a $205.00 target price on shares of Repligen in a research note on Thursday, September 26th. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a research note on Friday, November 22nd. Finally, Wolfe Research initiated coverage on Repligen in a research note on Thursday, November 14th. They issued a “peer perform” rating on the stock. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, Repligen presently has an average rating of “Moderate Buy” and an average target price of $190.25.

Repligen Trading Up 2.9 %

RGEN opened at $160.92 on Tuesday. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The firm has a market cap of $9.02 billion, a price-to-earnings ratio of -434.92, a PEG ratio of 4.64 and a beta of 0.96. Repligen Co. has a 12 month low of $113.50 and a 12 month high of $211.13. The stock has a fifty day moving average price of $142.66 and a 200-day moving average price of $141.59.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The business had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. During the same period in the prior year, the firm posted $0.23 earnings per share. The company’s quarterly revenue was up 9.7% on a year-over-year basis. As a group, equities research analysts anticipate that Repligen Co. will post 1.54 earnings per share for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.